Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:3/30/2009

PRINCETON, N.J., March 30 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the upcoming Citi Fourth Annual Biotech Day Conference and the Canaccord Adams Hepatitis C Conference. The Citi conference will be held in New York (April 1), while the Canaccord Adams conference will be held at the InterContinental The Barclay New York Hotel in New York City (April 7).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the Company at the Citi conference on Wednesday, April 1, 2009 at 4:00 PM (ET) and review the Company's HCV drug pipeline at the Canaccord Adams conference on Tuesday, April 7, 2009 at 1:30 PM (ET).

To access a simultaneous webcast of Mr. Price's presentations via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing four product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America, Europe, Japan and Taiwan. Clevudine is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. An IND for PSI-7851, a second generation nucleotide HCV inhibitor was filed in January 2009. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended December 31, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. Pharmasset to Present at Two Upcoming Investor Conferences
9. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
10. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to feel uncomfortable about ... than regular municipal or well water. The recent experience with lead contaminated water in ... a long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... -- --> --> ... & Delivery) and Neonatal Care Equipment Market Ultrasound, Doppler, ... Management Devices, CPAP, Capnograph, & Resuscitator) - Global Forecast ... global market over the forecast period of 2015 to ... in 2015 and is poised to grow at a ...
(Date:2/5/2016)... , February 5, 2016 ... Today, VoicePower Ltd - The Speech Recognition People, announced their ... deployed to improve patient care, reduce turnaround times and to save ... CCG ,- VoicePower client since 2013 Challenge: --> ... Challenge: --> - Six doctors ,- Wirral CCG ,- ...
(Date:2/5/2016)... http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ) has ... Obstetrics Partnering 2010-2016: Deal trends, players and ... --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ) has announced ... Partnering 2010-2016: Deal trends, players and financials" ... --> Research and Markets ( http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ...
Breaking Medicine Technology: